EP0163317B1 - Dérivés de la quinone, procédé de préparation, leur application et composition pharmaceutique - Google Patents
Dérivés de la quinone, procédé de préparation, leur application et composition pharmaceutique Download PDFInfo
- Publication number
- EP0163317B1 EP0163317B1 EP85106732A EP85106732A EP0163317B1 EP 0163317 B1 EP0163317 B1 EP 0163317B1 EP 85106732 A EP85106732 A EP 85106732A EP 85106732 A EP85106732 A EP 85106732A EP 0163317 B1 EP0163317 B1 EP 0163317B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- pharmaceutical composition
- compounds
- quinone derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
Definitions
- the invention relates to novel quinone derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same.
- the quinone derivatives of the invention provide a phospholipase inhibition effect, an antiplatelet effect and a therapeutic and/or preventive effect to cardiac diseases.
- the invention also relates to the use of the novel quinone derivatives for preparing a pharmaceutical composition.
- the invention provides a process for manufacturing the novel quinone derivatives.
- Ubidecarenone which is also called coenzyme Q 10 or ubiquinone 1o , was isolated from mitochondria in bovine cardiac muscle in a crystalline form by Crane et al. in 1957. It widely occurs in vivo, in particular in mitochondria in cells, and is an important constituent of a mitochondrial electron transport system governing energy production.
- p.76 C44 discloses specific quinone compounds of the general formula in which n is an integer of 1 to 10, R 1 is methyl-methoxy and R2is hydrogen or lower alkyl.
- the known quinone compounds are hypertensives, lenitives, anti-ulcers, anti-inflammatory agents, diuretics, anti- thrombotics, cerebral circulation improving agents and do show also an activity of regulating prostaglandin biosynthesis and effect to block adrenergic activity response.
- the present invention comprises a quinone derivative of the formula (I) in which X and Y are either the same as or different from each other and each are hydroxy, methoxy or hydrogen; and n is an integer of 1 to 5, or a pharmaceutically acceptable salt thereof.
- novel quinone derivative of formula (I) of claim 1 can be prepared by reacting in a manner known per se a compound of the formula (II): in which X and Y have the definition as in formula (I) in claim 1 with a compound of formula (III): in which n is an integer of 1 to 5 and R is hydrogen or a lower alkyl group.
- the reaction is carried out in the presence of a catalyst such as silica gel/zinc chloride.
- R in formula (III) represents a lower alkyl group, it may be hydrolyzed with caustic potash or caustic soda to form a carboxylic acid.
- the compound of the present invention exhibits a remarkably excellent phospholipase inhibition effect as well as antiplatelet effect, which makes it useful, e.g. as an antiplatelet, a blood compatible agent and a therapeutic agent for various cardiac diseases. More particularly it is available in treating and/or preventing cerebrovascular diseases such as TIA (transient ischenuc attack), cerebroinfarct (thrombi and emboli) and cerebral arteriosclerosis; postoperative thrombi, emboli and blood stream disorders accompanying vascular operations and extracorporea blood circulation; peripheral blood stream disorders caused by emboli or constriction of limb artery such as Buerger's disease, arteriosclerosis obliterans, SLE and Raynaud's disease; congestive failure accompanied by edema, pulmponary congestion or hepatomegaly; and cardiac diseases such as stenocardia and myocardial infarction.
- the compound of the present invention is further effective in preventing relapse of the foregoing diseases and treating the recuper
- the compound of the present invention is furthermore effective in treating and/or preventing inflammatory diseases such as various rheumatic diseases.
- Table 1 shows the result. Each value in Table 1 represents the evaluation of the corresponding compound assuming the value of a physiological saline solution as 100 and indicates the phospholipase A 2 inhibition activity thereof.
- Platelet agglutination test was carried out in the following manner with the use of PAF (platelet activating factor; 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine), collagen and ADP as inducers.
- PAF platelet activating factor; 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine
- collagen and ADP as inducers.
- Blood was collected from the venae brachiales of a healthy male adult in an amount of nine parts by volume to one part by volume of 3.8% sodium citrate solution. The blood was centrifuged at 100 x g for eight min and PRP separated as the supernatant was collected.
- Table 2 obviously indicates that the compounds of the present invention exert better antiplatelet effects than that of CoQ 10 .
- the concentrate was dissolved in 50 ml of ethanol and 3 g of caustic soda was added thereto. After refluxing for 30 min, the reaction mixture was poured into diluted hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate, concentrated and purified with silica gel chromatography with the use of ethyl acetate/benzene as the eluent to give 1.7 g of the title compound as a colorless oil.
- Example 2 The procedures of Example 1 were repeated except that 5 g of 2,3,4-trimethoxy-5-methylphenol and 3.2 g of 20-hydroxy-2,6,10,14,18-pentamethyl-2,6,10,14,18-eicosapentaenoic acid were employed as the starting materials to give 2.8 g of the title compound as a colorless oil.
- Example 2 The procedures of Example 1 were repeated except that 5 g of 2,3,4-trimethoxy-5-methylphenol and 3.5 g of 24-hydroxy-2,6,10,14,18,22-hexamethyl-2,6,10,14,18,22-tetracosahexaenoic acid were employed as the starting materials to give 2.5 g of the title compound as a colorless oil.
- Table 3 shows physiochemical properties of the compounds of the present invention as prepared in Examples 1 to 5.
- the compounds A to G of the present invention were orally administered to male ddY mice of approximately 25 to 30 g in body weight to thereby examine the acute toxicity thereof. Consequently each compound showed LO so of at least 500 mg/kg.
- the compounds A to G of the present invention were injected into the tail veins of 10 mice as described above in doses of 10, 30 and 100 mg/kg. The mice showed a survival ratio of 100% (i.e. 10/10) in each case, which suggests that the LO so of each compound is at least 100 mg/kg.
- the compound of the present invention exhibits a phospholipase inhibition effect as well as an antiplatelet effect and may be formulated into drugs such as an antiplatelet, a blood compatible agent and a therapeutic and/or preventive agent for cardiac diseases or inflammatory diseases including rheumatic diseases for oral or parenteral, e.g. intramuscular, hypodermical or intravenous administration or as a suppository.
- the compounds may be administered to an adult usually in a dose of approximately 10 to 1,000 mg, preferably approximately 50 to 500 mg, per day depending on the disease, condition and age of the patient.
- the compound of the present invention may be formulated into various forms such as a tablet, granules, a powder, a capsule, an injection or a suppository in a conventional manner.
- a solid drug for oral administration may be prepared by mixing the active compound(s) with excipient(s) and, if necessary, binder(s), disintegrating agent(s), lubricant(s), colorant(s) and corrigent(s) and formulating the obtained mixture into a tablet, a coated tablet, granules, a powder or a capsule in a conventional manner.
- excipient lactose, corn starch, sucrose, glucose, sorbitol and crystalline cellulose.
- binder polyvinyl alcohol, polyvinyl ether, ethylcellulose, methylcellulose, gum arabic, gum tragacanth, gelatin, shellac wax, hydroxypropylcellulose, hydroxypropylstarch and polyvinylpyrrolidone.
- disintegrating agent starch, agar, powdery gelatin, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, calcium citrate, dextrin and pectin.
- lubricant are magnesium stearate, talc, polyethylene glycol, silica and hardened vegetable oils.
- compositions may be added.
- examples of the corrigent are cacao powder, peppermint extract, aromatic acids, peppermint oil, Borneo camphor and cinnamon powder.
- the tablet or granules thus prepared may be optionally coated with an appropriate material such as sugar or gelatin.
- a hypodermical, intramuscular or intravenous injection may be prepared by adding desired pH adjustor(s), solubilizer(s), suspending agent(s), buffer(s), stabilizer(s), and preservative(s) to the active compound(s) and treated the mixture in a conventional manner.
- the ingredients as shown above were formulated into granules in a conventional manner and packed in gelatin hard capsules.
- the compound B, Nikkol HCO-60, sesame oil and a half amount of the propylene glycol were mixed together and heated to approximately 80°C for dissolution.
- Phosphate buffer solution, sodium chloride and the residual propylene glycol previously dissolved in distilled water and heated to approximately 80°C were added thereto to give an aqueous solution of 1,000 ml in total volume. 1 ml portions of the aqueous solution were poured into ampuls, which were then sealed and sterilized by heating.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT85106732T ATE36699T1 (de) | 1984-05-31 | 1985-05-31 | Chinonderivate, verfahren zu ihrer herstellung, ihre verwendung und pharmazeutische zusammensetzung. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59111555A JPS60255749A (ja) | 1984-05-31 | 1984-05-31 | キノン誘導体 |
JP111555/84 | 1984-05-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0163317A1 EP0163317A1 (fr) | 1985-12-04 |
EP0163317B1 true EP0163317B1 (fr) | 1988-08-24 |
Family
ID=14564354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP85106732A Expired EP0163317B1 (fr) | 1984-05-31 | 1985-05-31 | Dérivés de la quinone, procédé de préparation, leur application et composition pharmaceutique |
Country Status (8)
Country | Link |
---|---|
US (1) | US4992469A (fr) |
EP (1) | EP0163317B1 (fr) |
JP (1) | JPS60255749A (fr) |
AT (1) | ATE36699T1 (fr) |
CA (1) | CA1270844A (fr) |
DE (1) | DE3564566D1 (fr) |
IL (1) | IL75337A (fr) |
SU (2) | SU1442068A3 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE153655T1 (de) * | 1990-02-08 | 1997-06-15 | Eisai Co Ltd | Benzensulfonamidderivat |
US5393776A (en) * | 1990-09-14 | 1995-02-28 | Bristol-Myers Squibb Company | Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia |
AU4510596A (en) * | 1994-12-06 | 1996-06-26 | National Research Council Of Canada | Water soluble ubiquinone compositions, prodrugs, and methods relating thereto |
US6458952B1 (en) * | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
US6664255B1 (en) * | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
US6906068B1 (en) | 1999-05-19 | 2005-06-14 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants |
US6908919B2 (en) * | 1999-05-19 | 2005-06-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
US6653316B1 (en) | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US6716838B1 (en) | 1999-05-19 | 2004-04-06 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
US6867217B1 (en) | 1999-05-19 | 2005-03-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade |
US6750342B1 (en) * | 1999-05-19 | 2004-06-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
US7015230B1 (en) | 1999-05-19 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
WO2001068605A1 (fr) | 2000-03-13 | 2001-09-20 | Pharmacia Corporation | Benzenes polycycliques substitues aryle et heteroaryle utiles pour l'inhibition selective de la cascade de coagulation |
WO2001077097A2 (fr) * | 2000-04-05 | 2001-10-18 | Pharmacia Corporation | 4-pyrones polycycliques a substitution aryle et heteroaryle utiles pour l'inhibition selective de la cascade de coagulation |
CA2405306A1 (fr) | 2000-04-05 | 2001-10-18 | Pharmacia Corporation | Pyridones polycycliques 4-aryl et heteroaryl substituees utiles pour l'inhibition selective de la cascade de coagulation |
US20040171616A9 (en) | 2000-04-17 | 2004-09-02 | South Michael S. | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
US7119094B1 (en) | 2000-11-20 | 2006-10-10 | Warner-Lambert Company | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade |
CA2430037A1 (fr) * | 2000-11-20 | 2002-05-30 | Michael S. South | Aryl-et-heteroaryl-pyridines polycycliques substituees utiles dans l'inhibition selective de la cascade de la coagulation |
US7015223B1 (en) | 2000-11-20 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade |
US20030236257A1 (en) * | 2001-04-04 | 2003-12-25 | South Michael S. | Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the cogulation cascade |
US20040082585A1 (en) * | 2001-10-03 | 2004-04-29 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
BR0213099A (pt) * | 2001-10-03 | 2004-10-19 | Pharmacia Corp | Compostos policìclicos de 5 membros substituìdos úteis para inibição seletiva da cascata de coagulação |
CA2462305A1 (fr) * | 2001-10-03 | 2003-04-10 | Michael S. South | Composes heterocycliques a 6 chainons utiles dans l'inhibition selective de la cascade de la coagulation |
CA2462647A1 (fr) * | 2001-10-03 | 2003-04-10 | Michael S. South | Composes heterocycliques insatures a 6 chainons utiles pour l'inhibition selective de reactions en cascade de la coagulation |
US20040068113A1 (en) * | 2001-11-20 | 2004-04-08 | South Michael S. | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
WO2005034945A1 (fr) * | 2003-10-11 | 2005-04-21 | Thierry Schwitzguebel | Utilisation de la norphenazone et de coenzyme q pour le traitement de l'arthrose, l'arthrite et l'osteo-arthrite |
JP2006045187A (ja) * | 2003-12-25 | 2006-02-16 | Bio Igaku Kenkyusho Kk | 臓器不全治療剤 |
JP2006069958A (ja) * | 2004-09-02 | 2006-03-16 | Bio Igaku Kenkyusho Kk | 老化防止剤 |
US7528271B2 (en) * | 2007-05-16 | 2009-05-05 | Bergen Teknologioverforing As | Intermediates, process for their preparation and synthesis of 1,4-benzoquiones |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957836A (en) * | 1973-07-02 | 1976-05-18 | Takeda Chemical Industries, Ltd. | Quinone derivatives |
JPS5640651A (en) * | 1979-09-12 | 1981-04-16 | Takeda Chem Ind Ltd | Quinone compound and its preparation |
JPS567737A (en) * | 1979-07-02 | 1981-01-27 | Takeda Chem Ind Ltd | Physiologically active quinone and its preparation |
JPS5697223A (en) * | 1979-12-30 | 1981-08-05 | Takeda Chem Ind Ltd | Tissue metabolism activator |
JPS58177934A (ja) * | 1982-04-13 | 1983-10-18 | Takeda Chem Ind Ltd | ベンゾキノン誘導体 |
-
1984
- 1984-05-31 JP JP59111555A patent/JPS60255749A/ja active Granted
-
1985
- 1985-05-29 IL IL75337A patent/IL75337A/xx unknown
- 1985-05-29 US US06/738,936 patent/US4992469A/en not_active Expired - Lifetime
- 1985-05-30 SU SU853900664A patent/SU1442068A3/ru active
- 1985-05-30 CA CA000482757A patent/CA1270844A/fr not_active Expired - Fee Related
- 1985-05-31 AT AT85106732T patent/ATE36699T1/de not_active IP Right Cessation
- 1985-05-31 DE DE8585106732T patent/DE3564566D1/de not_active Expired
- 1985-05-31 EP EP85106732A patent/EP0163317B1/fr not_active Expired
-
1986
- 1986-03-18 SU SU864027118A patent/SU1447276A3/ru active
Also Published As
Publication number | Publication date |
---|---|
CA1270844A (fr) | 1990-06-26 |
IL75337A0 (en) | 1985-09-29 |
ATE36699T1 (de) | 1988-09-15 |
EP0163317A1 (fr) | 1985-12-04 |
US4992469A (en) | 1991-02-12 |
IL75337A (en) | 1989-02-28 |
JPH056533B2 (fr) | 1993-01-26 |
SU1447276A3 (ru) | 1988-12-23 |
JPS60255749A (ja) | 1985-12-17 |
DE3564566D1 (en) | 1988-09-29 |
SU1442068A3 (ru) | 1988-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0163317B1 (fr) | Dérivés de la quinone, procédé de préparation, leur application et composition pharmaceutique | |
US4613593A (en) | Therapeutic and preventive agent containing dolichol | |
EP0202589B1 (fr) | Composés pharmaceutiques qui contient des dérivés de l'acide ascorbique | |
CA1205083A (fr) | Composes anti-protozoaires | |
EP0002228B1 (fr) | Dérivés d'hydroxynaphtochinones, leurs préparations utilisées dans le traitement et la prévention de la theilériose chez le bétail et les moutons; leurs procédés de préparation; dérivés de naphtoquinones | |
EP0154887B1 (fr) | 2,5-Diaryl tétrahydrothiophénes et analogues, en tant qu'antagonistes de PAF | |
US4831054A (en) | 2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia | |
US4269851A (en) | 8-Aminoalkyl-4-alkylpsoralens | |
HU189569B (en) | Process for preparing 2-substituted phenyl/-benzoic acids and pharmaceutical compositons containing such compounds as active substances | |
Samhoun et al. | Actions and interactions of lipoxygenase and cyclo-oxygenase products in respiratory and vascular tissues | |
FR2521992A1 (fr) | Nouveaux composes de pyridine utiles comme medicaments | |
KR970002470B1 (ko) | 아스코르빈산 유도체 | |
US4167566A (en) | Antithrombotic 2-prenyl-3-oxo-5,6-diaryl-as-triazenes | |
US3870792A (en) | Certain dihydrophthalizines for treating hemorrhage and thrombosis | |
US4628062A (en) | 1,4-naphthoquinone derivatives having anti-inflammatory action | |
US3880932A (en) | 4-(2-Naphthyl)-4-alkyl-3-buten-2-ones | |
US4603126A (en) | Therapeutic and preventive agent containing dolichol | |
EP0128374B1 (fr) | Composition préventive et curative pour maladies causées par les produits métaboliques de la lipoxigenase | |
US4599328A (en) | Therapeutic and preventive agent containing dolichol | |
US4461912A (en) | Phenylacetic acid derivatives, their preparation and compositions containing them | |
US4791105A (en) | Therapeutic and preventive agent containing dolichol | |
JPS6212773A (ja) | ヘキセン酸、その製造法及びこれを含有する製薬組成物 | |
JPH0514708B2 (fr) | ||
EP0149847A2 (fr) | Agent thérapeutique et préventif contenant le dolichol | |
JPH0635384B2 (ja) | キノン誘導体を有効成分とする医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19860305 |
|
17Q | First examination report despatched |
Effective date: 19860827 |
|
D17Q | First examination report despatched (deleted) | ||
ITF | It: translation for a ep patent filed |
Owner name: FUMERO BREVETTI S.N.C. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI NL SE |
|
REF | Corresponds to: |
Ref document number: 36699 Country of ref document: AT Date of ref document: 19880915 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3564566 Country of ref document: DE Date of ref document: 19880929 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
ITTA | It: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 85106732.2 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUEA Free format text: EISAI CO., LTD;NAGOYA UNIVERSITY TRANSFER- NAGOYA UNIVERSITY |
|
NLS | Nl: assignments of ep-patents |
Owner name: NAGOYA UNIVERSITY |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20030507 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20030508 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20030514 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20030528 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20030530 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20030531 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20030612 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20030725 Year of fee payment: 19 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040601 |
|
BERE | Be: lapsed |
Owner name: *NAGOYA UNIVERSITY Effective date: 20040531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041201 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041201 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050131 |
|
EUG | Se: european patent has lapsed | ||
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20041201 |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |